Litcius/Paper detail

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages

Haithuy Pham, Whitney Medford, Spencer Horst, Melissa Levesque, David Ragoonanan, Christine Price, Harold J. Colbassani, Keaton Piper, Keith Chastain

2022The American Journal of Emergency Medicine51 citationsDOI

Topics & Concepts

MedicineRivaroxabanApixabanProthrombin complex concentrateHemostasisIntracerebral hemorrhageAnesthesiaThrombosisEmergency medicineSurgeryInternal medicineGlasgow Coma ScaleWarfarinAtrial fibrillationIntracerebral and Subarachnoid Hemorrhage ResearchAtrial Fibrillation Management and OutcomesSpinal Hematomas and Complications
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages | Litcius